Chinese Medicine Regulates DNA Methylation to Treat Haematological Malignancies: A New Paradigm of "State-Target Medicine"

Chin J Integr Med. 2022 Jun;28(6):560-566. doi: 10.1007/s11655-021-3316-7. Epub 2021 Jul 9.

Abstract

Aberrant regulation of DNA methylation plays a crucial causative role in haematological malignancies (HMs). Targeted therapy, aiming for DNA methylation, is an effective mainstay of modern medicine; however, many issues remain to be addressed. The progress of epigenetic studies and the proposed theory of "state-target medicine" have provided conditions to form a new treatment paradigm that combines the "body state adjustment" of CM with targeted therapy. We discussed the correlation between Chinese medicine (CM) syndromes/states and DNA methylation in this paper. Additionally, the latest research findings on the intervention and regulation of DNA methylation in HMs, including the core targets, therapy status, CM compounds and active components of the Chinese materia medica were concisely summarized to establish a theoretical foundation of "state-target synchronous conditioning" pattern of integrative medicine for HMs, simultaneously leading a new perspective in clinical diagnosis and therapy.

Keywords: Chinese medicine; DNA methylation; haematological malignancies; state-target medicine.

MeSH terms

  • DNA Methylation / genetics
  • Drugs, Chinese Herbal*
  • Hematologic Neoplasms* / drug therapy
  • Hematologic Neoplasms* / genetics
  • Humans
  • Materia Medica*
  • Medicine, Chinese Traditional

Substances

  • Drugs, Chinese Herbal
  • Materia Medica